RecruitingNot ApplicableNCT05895344

Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study

Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma


Sponsor

Centre Francois Baclesse

Enrollment

160 participants

Start Date

Feb 26, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Cavernous sinus meningiomas are close to optic nerve, pituitary gland, cranial nerve, and hippocampi. The doses delivered to these structures are crucial and radiotherapy of cavernous sinus meningiomas exposes patients to late secondary effects (pituitary deficit, nerve palsy, cognitive impairment…). In 2012, Gondi reported that a dose given to 40% of the bilateral hippocampi greater than 7.3 Gy is associated with long-term impairment in list-learning delayed recall after FSRT for benign or low-grade adult brain tumors. There is no published or recruiting prospective study evaluating the impact of proton-therapy or conventional irradiation on neurocognitive function for meningioma patients. Notably, long-term cognitive or ocular impact of these modern irradiation schemes remains poorly known. Yet, these patients had a long life-expectancy, and are at risk of developing long-term sequelae. Thus, according to its ballistic advantage, an improvement of patient functional outcomes and a reduction of neurocognitive long-term toxicity are expected if tissue sparing proton-therapy is used. In this context, a randomized prospective study, evaluating long-term toxicity of these two irradiation modalities (Proton Therapy (PRT) and photon radiotherapy (XRT)) seems crucial to further assess proton-therapy indication for these patients. Although literature reports excellent outcomes for intracranial meningioma patients treated by proton-therapy, none of the eight retrospective studies found in the literature used an accurate and full evaluation of long-term toxicity


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Photon radiotherapy and Proton-therapy for people with cavernous sinus meningioma, cognitive impairment, and other related conditions. The study is currently recruiting participants at 13 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONProton-therapy

Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)

RADIATIONPhoton radiotherapy

Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)


Locations(13)

Centre Francois Baclesse

Caen, France

Hopital d'Instruction des Armées PERCY

Clamart, France

CHU Grenoble-Alpes

Grenoble, France

Centre Guillaume le Conquerant

Le Havre, France

Centre Léon Bérard

Lyon, France

Hospices civils de Lyon

Lyon, France

Centre Antoine Lacassagne

Nice, France

Hôpital Pitié Salpétrière

Paris, France

Institut Curie

Paris, France

Institut Curie

Saint-Cloud, France

Centre Paul Strauss

Strasbourg, France

IUCT

Toulouse, France

Gustave Rousy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05895344


Related Trials